Skip to main content
Download PDF

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Critical Care volume 24, Article number: 331 (2020) Cite this article

A Letter to this article was published on 20 August 2020

A Letter to this article was published on 27 July 2020

Abstract

Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.

COVID-19 infection

The COVID-19 pandemic has rapidly brought down not only the public health but also the social issues and the global economy, owing to the uncertainties surrounding the characteristics of the virus, the lack of a vaccine, and the relatively scarce effectiveness of currently available antiviral treatments (i.e. RNA-dependent RNA polymerase inhibitors in combination with hydroxychloroquine in patients with severe pneumonia) [1, 2].

In symptomatic patients, the infection can evolve towards a severe inflammatory response, involving several organs with lung injury and bilateral interstitial pneumonia. In this setting, acute respiratory distress syndrome (ARDS) can occur, and intensive care unit (ICU) along with mechanical ventilation is required [3]. Worldwide, among the current primary needs of healthcare systems, there is the implementation of measures that can improve the sustainability of the number of patients requiring hospitalization and ICU admission. In this scenario, the use of existing therapeutic options, able to mitigate the disease severity, could contribute to achieve this goal. In the present article, we discuss the main drugs known to exert immunomodulatory effects by targeting the cytokine pathways that may represent promising strategies for the management of COVID-19-related ARDS and pneumonia.

The cytokine storm

The majority of patients with COVID-19 infection shows alterations of white blood cell counts, in particular lymphocytopenia. In patients requiring ICU admission, an increase in neutrophil count, D-dimer, blood urea, and creatinine levels have been detected as well as more severe lymphocytopenia. This condition is defined as a “cytokine storm” and is associated with high circulating levels of interleukins (IL)-2, IL-6, IL-7, IL-10, granulocyte colony-stimulating factor (G-CSF), 10 kDa interferon-gamma-induced protein (IP-10), monocyte chemo-attractant protein-1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), and tumor necrosis factor (TNF) [4, 5]. In particular, in ARDS patients, a strong depletion of peripheral blood T cells, along with a decreased recruitment of lymphocytes and neutralizing antibodies and an increased production of cytokines, was detected in the lungs [6]. This network of pathogenic factors is thought to drive a severe immune-mediated interstitial pneumonia and a delayed pulmonary clearance of COVID-19 [3].

Current evidence supports a close relationship between cytokine storm and disease severity. Indeed, ICU patients displayed higher serum levels of cytokines (G-CSF, IP-10, MCP-1, MIP-1α, and TNF–α) than those not requiring ICU. For instance, IL-6 and TNF-α levels in ICU patients were significantly higher when compared with non-ICU ones [7]. Patients with fatal outcome had higher serum concentrations of IL-6 than those survived: the IL-6 median levels reported by Zou et al. were 11.00 pg/mL (IQR 7.50–14.40) and 6.30 pg/mL (IQR 5.00–7.90), respectively, p < 0.0001. Similar findings were showed by Ruan et al. 11.4 pg/mL (IQR 8.5) in dead patients versus 6.8 pg/mL (IQR 3.61) in discharged ones [8, 9]. Furthermore, a significantly close relationship between IL-6 levels in critical COVID-19 patients with fatal outcome (64.0 pg/ml, IQR 25.6–111.9) and RNAemia was found, in particular, the 83.3% of patients with IL-6 > 100 pg/ml had positive levels of RNAemia, r 0.902. This suggests that high serum IL-6 along with RNAemia could be predictors of mortality [10]. Additionally, not only critically ill patients with ARDS have been associated with high cytokine serum levels but also non-severe patients with COVID-19. Indeed, IL-6 median serum levels were 36.10 pg/mL (IQR 23.00–59.20) in severe patients compared with 10.60 pg/mL (IQR 5.13–24.18) in those with mild disease, p 0.002 [11], and 6.69 pg/mL (IQR 4.44–12.43) in patients with SpO2 ≥ 90% in comparison with 51.69 pg/mL (IQR 34.31–161.65) in those with SpO2 < 90%, p < 0.001, as well as the TNF-α levels (2.08 pg/mL, IQR 1.93–2.35 even in the conditions with SpO2 ≥ 90%) [12]. These data were confirmed by Qin et al.; IL-6 median serum levels in severe and non-severe patients were 25.2 pg/mL (IQR 9.5–54.5) and 13.3 pg/mL (IQR 3.9–41.1), respectively; and TNF-α median serum levels were 8.7 pg/mL (IQR 7.1–11.6) in severe patients and 8.4 pg/mL (IQR 6.9–10.4) in non-severe ones [6].

Based on this knowledge, it has been proposed that the modulation of the above cytokines could represent an interesting approach to improve the prognosis of patients with COVID-19 pulmonary complications, both pneumonia and ARDS. Recently, The Food and Drug Administration has allowed the emergency use of a device aiming at purifying blood of ICU patients from the cytokine storm [13].

Potential therapeutic target drugs

Several drugs, endowed with modulating activity on cytokine pathways, including anti-IL-6, anti-TNF, and Janus kinase (JAK) inhibitors, currently approved for the treatment of immune-mediated inflammatory diseases, have been suggested or could be yet taken into account for experimental use in COVID-19 patients with ARDS and/or pneumonia (Fig. 1).

Fig. 1
figure 1

Cytokine storm and potential pharmacological targets in COVID-19-related ARDS and pneumonia. IL, interleukin; TNF, tumor necrosis factor, GCSF, granulocyte colony-stimulating factor; JAK, Janus kinase; MCP, monocyte chemoactractant protein; MIP, macrophage inflammatory protein

Full size image

Anti-IL-6

Tocilizumab is a humanized, immunoglobulin G1κ (IgG1κ) anti-human IL-6 receptor (IL-6R) monoclonal antibody approved for some immune-mediated inflammatory rheumatic diseases. Clinical evidence supports the view that this drug is an effective therapeutic option, with a good risk-benefit profile, in cytokine storm syndromes [14]. In China, its off label use has been tested in 21 ICU ARDS patients with favorable results after 24–48 h in 20/21 patients [15]. Moreover, a multicenter randomized clinical trial in COVID-19 patients with ARDS, treated with tocilizumab at a dose of 4 ~ 8 mg/kg once, and an additional same dose when fever persists within 24 h after the first administration, has been approved in China [16]. The Italian Medicine Agency has recently authorized a trial on the use of tocilizumab in COVID-19 patients with ARDS [17]. This initiative was pushed on also by promising results published on Italian newspapers. Particularly, some patients treated with tocilizumab at the “Pascale” Cancer Institute in Naples showed disease improvements within 24 h and one of them did not require mechanical ventilation 2 days after starting tocilizumab [15].

Another monoclonal antibody belonging to anti-IL-6 drug class, siltuximab, currently approved in multicentric Castleman disease with HIV-negative and human herpesvirus-8 negative, is under investigation for ARDS in COVID-19 patients. In particular, an observational case-control study evaluating siltuximab in ICU patients with ARDS-related COVID-19 is performing at Papa Giovanni XXIII hospital in Bergamo, Italy [18]. Preliminary results have shown promising outcomes as the clinical improvement in the 33% of treated ICU patients [19]. In addition, a multicenter open-label randomized clinical trial is studying the benefit risk profile of siltuximab, as a single therapeutic option or in combination with anakinra, at a single dose of 11 mg/kg, in comparison with tocilizumab or anakinra, alone or in combination, in ARDS patients with COVID-19 [20]. Evidence suggested a higher binding affinity to IL-6 involving siltuximab than tocilizumab but less insights are currently available on the effects of siltuximab in cytokine storm [21].

Based on the results expected with tocilizumab and siltuximab, other anti-IL-6 drugs, currently approved for rheumatoid arthritis, namely sarilumab and sirukumab, could be studied in ARDS and pneumonia patients with COVID-19. Notably, sarilumab has higher affinity for its target and a longer half-life than tocilizumab; thus, a sustained therapeutic effect could be achieved by administration of only one single dose [22, 23]. On March 19th, 2020, a clinical trial evaluating the efficacy and safety of high dose and low dose of sarilumab in COVID-19 patients was started [24]. Subsequently, further clinical trials have followed, investigating the benefit risk profile of sarilumab in patients with COVID-19-related ARDS, at a dose of 200 mg or 400 mg, as single or repeated administration, subcutaneously or intravenously [25,26,27,28].

Sirukumab neutralizes IL-6 specifically and directly by preventing its binding to its membrane receptor [29], and thus, it leads to a subsequent suppression of IL-6 biological actions. In a phase I trial, sirukumab showed linear pharmacokinetics with long half-life, low immunogenicity, and a good safety profile [30]. Accordingly, it could represent a promising pharmacological option for counteracting the high IL-6 levels occurring in ARDS patients.

Anti-TNF

Anti-TNF drugs, including infliximab, adalimumab, etanercept, golimumab, and certolizumab, could be tested also for COVID-19-related ARDS and pneumonia. In China, a clinical trial on adalimumab in COVID-19 patients was recently approved [31]. Infliximab, adalimumab, and golimumab are IgG1 monoclonal antibodies, while etanercept is a fusion protein of two human TNF type 2 receptor moieties linked with the Fc region of a human immunoglobulin, and certolizumab is the pegylated Fab domain obtained from a humanized anti-TNF IgG monoclonal antibody [32]. Differences in the inhibitory mechanism were shown among these drugs, due to their different molecular binding patterns with TNF sites [33]. All anti-TNF drugs display higher binding affinity to soluble TNF than its membrane-bound form, with golimumab and etanercept showing the highest level [34]. Greater binding avidity to soluble TNF was reported for etanercept than infliximab and adalimumab [35]. Heterogeneity was also found in the neutralizing activity of anti-TNF drugs to soluble TNF, while that to transmembrane TNF was comparable [34]. Infliximab and adalimumab displayed a greater binding activity for FcγRII and FcγRIII than etanercept, but the latter was able to bind FcγRI with higher affinity [36]. FcγRs play important roles in the modulation of immune responses, which rely on cytokines and vasoactive mediators [37]. In addition, a review showed that the proteins coded by the virus alter the complement system control and thus contribute to lung viral damages [3]. Out of the anti-TNF drugs, the IgG1 monoclonal antibodies have a complement-dependent cytotoxicity activity [38] that could be explored in the COVID-19 infection. The known differences in pharmacokinetics and pharmacodynamics among anti-TNF drugs support the need for testing these agents in COVID-19-related ARDS and pneumonia patients without particular priorities, in order to identify the best option. Other selection criteria, including the administration route, the possible positive or negative interactions resulting from combination with other drugs (i.e., hydroxychloroquine) and the costs (i.e., the use of biosimilar anti-TNF available) should be considered.

JAK inhibitors

Anti-JAK drugs (such as ruxolitinib, tofacitinib, baricitinib, oclacitinib, fedratinib, upadacitinib, and peficitinib) [39] should be considered also among the options for clinical investigations in COVID-19-related ARDS and pneumonia patients. JAKs are involved in JAK/STAT signaling associated with the receptors of a large variety of cytokines. In particular, STAT-1 and STAT-3 pathways are activated by binding of IL-6 to its receptor (IL-6R) [40]. Tofacitinib acts as a non-selective inhibitor of all known JAKs (JAK1, JAK2, JAK3, TYK2) with moderate specificity for JAK1 and JAK3. Baricitinib inhibits selectively JAK1 and JAK2 [41]. Both are approved by the European Medicines Agency (EMA); baricitinib for rheumatoid arthritis and tofacitinib for both rheumatic disorders and ulcerative colitis. Ruxolitinib is a JAK1/JAK2 inhibitor approved by the Food and Drug Administration (FDA) for psoriasis, myelofibrosis, and rheumatoid arthritis. Upadacitinib (anti-JAK1), fedratinib (anti-JAK2), and oclacitinib (anti-JAK1) were approved by FDA for rheumatoid arthritis, myelofibrosis, and dermatitis, respectively [42]. Peficitinib (anti-JAK3) was approved for rheumatoid arthritis only in Japan [43].

Tofacitinib and upadacitinib showed potent inhibitory activities on JAK1/3-dependent cytokines, both pathways being involved in lymphocyte activation. Tofacitinib, baricitinib, and upadacitinib displayed also inhibitory actions on the JAK2/TYK2-dependent signaling of IL-3, GM-CSF, and G-CSF. Tofacitinib was shown to act as the most potent inhibitor of G-CSF (JAK2/TYK2). Moreover, tofacitinib, baricitinib, and upadacitinib inhibited IL-6 and interferon (IFN) γ (JAK1/2), as well as IL-10 and IFN-α (JAK1/TYK2), with tofacitinib appearing as the strongest inhibitor of IL-6, IFN-γ, and IL-10 signals [44]. Evidence suggests that baricitinib, fedratinib, and ruxolitinib are also inhibitors of numb-associated kinases (NAK), involved in viral endocytosis and replication. Baricitinib showed the highest affinity for AAK1 than ruxolitinib and fedratinib. Thus, besides exerting putative anti-inflammatory effects in ARDS patients, it is expected also to reduce viral infectivity [45, 46]. Of note, a clinical trial on such antiviral effect is going to start with ruxolitinib [47], and an open-label trial is evaluating its efficacy and safety at a dose of 10 mg twice a day in COVID-19 patients with ARDS [48]. Furthermore, an expanded access program of the 5 mg ruxolitinib formulation is ongoing in severe COVID-19 patients with ≥ 6 years old [49]. Finally, an open label clinical trial is evaluating the benefit risk profile of baricitinib at a dose of 2 mg a day for 10 days in moderate and severe adult COVID-19 patients [27]. Whenever JAK inhibitors could be identified as an effective pharmacological option in COVID-19-related ARDS and pneumonia, their cost and safety issues, particularly the risk of thromboembolic events for some of them, should be taken into account [50].

Conclusions

Several drugs targeting cytokine pathways hold the potential for providing benefits in COVID-19-related ARDS and pneumonia. Anti-IL-6, anti-TNF, and anti-JAK medications, currently available for treating other immune-dependent inflammatory diseases, are expected to exert favorable effects in this setting, based on their mechanism of action. In the current emergency situation and without reliable therapeutic options, their benefit risk-profile will likely be favorable. Cost and safety will be a priority at a later phase of the epidemic, when more robust data will be available.

Availability of data and materials

Not applicable.

Abbreviations

ARDS:

Acute respiratory distress syndrome

EMA:

European Medicines Agency

FDA:

Food and Drug Administration

G-CSF:

Granulocyte colony-stimulating factor

ICU:

Intensive care unit

IFN:

Interferon

IgG1κ:

Immunoglobulin G1κ

IL:

Interleukins

IL-6R:

Interleukin-6 receptor

JAK:

Janus kinase

IP-10:

10 kDa interferon-gamma-induced protein

MCP-1:

Monocyte chemo-attractant protein-1

MIP-1α:

Macrophage inflammatory protein 1α

RNA:

Ribonucleic acid

TNF:

Tumor necrosis factor

References

  1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun [Internet]. 2020 May 1 [cited 2020 may 12];109. Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32113704.

  2. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32173110.

  3. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32 [cited 2020 May 12] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/31981224.

    Article  CAS  Google Scholar 

  4. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11 [cited 2020 Mar 17] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32169119.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity reviews. Elsevier B.V.; 2020 [cited 2020 May 8]. p. 102537. Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32251717.

  6. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32161940.

  7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506 [cited 2020 Mar 17] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/31986264.

    Article  CAS  Google Scholar 

  8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62 [cited 2020 May 12] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=32171076.

    Article  CAS  Google Scholar 

  9. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32125452.

  10. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=32301997.

  11. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=32181911.

  12. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 Cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020 [cited 2020 May 12]; Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32176772.

  13. Coronavirus (COVID-19) Update: FDA Authorizes Blood Purification Device to Treat COVID-19 | FDA. [cited 2020 Apr 22]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-19.

  14. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95 [cited 2020 Mar 18] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/24876563.

    Article  CAS  Google Scholar 

  15. Coronavirus, tocilizumab: buoni risultati su due pazienti gravi. Urgente un protocollo per estendere uso del farmaco - la Repubblica. [cited 2020 Mar 19]. Available from: https://www.repubblica.it/oncologia/news/2020/03/11/news/coronavirus_buoni_risultati_su_due_pazienti_gravi_con_tocilizumab_ora_serve_un_protocollo_per_estendere_l_uso_del_farmaco-250937051/.

  16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4 [cited 2020 Mar 19] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=32192578.

    Article  CAS  Google Scholar 

  17. AIFA e Istituto Nazionale per lo studio e la cura dei tumori di Napoli avviano uno studio per l’utilizzo di Tocilizumab nella malattia COVID 19. [cited 2020 Mar 18]. Available from: https://www.aifa.gov.it/web/guest/-/aifa-e-istituto-nazionale-per-lo-studio-e-la-cura-dei-tumeri-di-napoli-avviano-uno-studio-per-l-utilizzo-di-tocilizumab-nella-malattia-covid-19.

  18. An observational case-control study of the use of siltuximab in ards patients diagnosed with COVID-19 infection - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT04322188?term=siltuximab&cond=Coronavirus&draw=2&rank=1.

  19. Positive early data from siltuximab COVID-19 trial - PharmaTimes. [cited 2020 Apr 8]. Available from: http://www.pharmatimes.com/news/positive_early_data_from_siltuximab_covid-19_trial_1334145.

  20. Treatment of COVID-19 patients with anti-interleukin drugs - Full text view - ClinicalTrials.gov. [cited 2020 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT04330638?term=siltuximab&cond=Coronavirus&draw=2&rank=2.

  21. Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019 ;15:323–35. [cited 2020 May 12] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/30880998.

  22. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017 ;11:1593–603. [cited 2020 may 12]Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/28579757.

  23. Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 - Full Text View - ClinicalTrials.gov. [cited 2020 Mar 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT04310228?term=tocilizumab&cond=Corona+Virus+Infection&draw=2&rank=1.

  24. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 - full text view - ClinicalTrials.gov. [cited 2020 Mar 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298?term=sarilumab&cond=Corona+Virus+Infection&draw=2&rank=1.

  25. Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients - SARILUMAB TRIAL - CORIMUNO-19 - SARI - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04324073?term=sarilumab&cond=Corona+Virus+Infection&draw=2&rank=1.

  26. Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04322773?term=sarilumab&cond=Corona+Virus+Infection&draw=2&rank=3.

  27. Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04321993?term=sarilumab&cond=Corona+Virus+Infection&draw=2&rank=4.

  28. Sarilumab COVID-19 - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04327388?term=sarilumab&cond=Corona+Virus+Infection&draw=2&rank=2.

  29. Tanaka Y. Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9):1595–7 [cited 2020 May 12] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/24833786.

    Article  CAS  Google Scholar 

  30. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72(2):270–81 [cited 2020 Mar 19] Available from: http://0-doi-wiley-com.brum.beds.ac.uk/10.1111/j.1365-2125.2011.03964.x.

    Article  CAS  Google Scholar 

  31. Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. 2020 [cited 2020 Mar 19]; Available from: http://arxiv.org/abs/2003.00751.

  32. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Therapeutics. 2008;117:244–79 [cited 2020 Mar 19] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/18155297.

    Article  CAS  Google Scholar 

  33. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of Adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–67.

    Article  CAS  Google Scholar 

  34. Shealy D, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2(4):428–39 [cited 2020 Mar 19] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/20519961.

  35. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308–16 [cited 2020 Mar 19] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/19188093.

    Article  CAS  Google Scholar 

  36. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–31 [cited 2020 Mar 19] Available from: http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/19128982.

    Article  CAS  Google Scholar 

  37. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nature Reviews Immunol. 8:2008, 34–47 [cited 2020 Mar 19] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/18064051.

  38. Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta SI, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα. Inflamm Bowel Dis. 2013;19(6):1224–31 [cited 2020 Apr 22] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=23619715.

    Article  Google Scholar 

  39. Fragoulis GE, Mcinnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58(1):i43–i54. [cited 2020 Mar 19] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=30806709.

  40. Malemud CJ. Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by pro-inflammatory cytokines: potential drug targets. Int J Interf Cytokine Mediat Res. 2010;2(1):97–111 Available from: https://0-www-scopus-com.brum.beds.ac.uk/inward/record.uri?eid=2-s2.0-78649385348&doi=10.2147%2FIJICMR.S9470&partnerID=40&md5=47a02c1ff933fdf8a6a438f05683879b.

    Article  CAS  Google Scholar 

  41. Bae SC, Lee YH. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2019;78(6):559–67 [cited 2020 Mar 18] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=30191390.

    Article  CAS  Google Scholar 

  42. U.S. Food and Drug Administration. [cited 2020 Mar 19]. Available from: https://www.fda.gov/.

  43. Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019 May 15;79(8):887–91.

    Article  CAS  Google Scholar 

  44. McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. [cited 2020 Jun 8] Available from: https://pubmed.ncbi.nlm.nih.gov/31375130/?from_single_result=31375130&show_create_notification_links=False.

  45. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 ;20(4):400–402. [cited 2020 May 12] Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/?term=32113509.

  46. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1 [cited 2020 May 12]Available from: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/pubmed/32032529.

    Article  CAS  Google Scholar 

  47. COVID-19 Registered Trials - and analysis - CEBM. [cited 2020 Mar 19]. Available from: https://www.cebm.net/oxford-covid-19/covid-19-registered-trials-and-analysis/.

  48. Treatment of SARS Caused by COVID-19 With Ruxolitinib - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04334044?term=ruxolitinib&cond=Corona+Virus+Infection&draw=2&rank=1.

  49. Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness - Full Text View - ClinicalTrials.gov. [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04337359?term=ruxolitinib&cond=Corona+Virus+Infection&draw=2&rank=2.

  50. Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs | European Medicines Agency. [cited 2020 Mar 18]. Available from: https://www.ema.europa.eu/en/news/restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs.

Download references

Acknowledgements

Not applicable.

Funding

No funding has been received to perform this article.

Author information

Authors and Affiliations

  1. Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello & Corrado Blandizzi

  2. Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy

    Marco Tuccori & Corrado Blandizzi

  3. North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

    Daniele Focosi

Authors
  1. Irma Convertino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Tuccori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Ferraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulia Valdiserra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emiliano Cappello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniele Focosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Corrado Blandizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IC, MT, and CB contributed to the idea; IC, MT, SF, GV, EC, DF, and CB to the data searching and interpretation; and IC, MT, and CB to the redaction of the manuscript and IC, MT, SF, GV, EC, DF, and CB reviewed the final version. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Marco Tuccori.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Convertino, I., Tuccori, M., Ferraro, S. et al. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care 24, 331 (2020). https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-020-03020-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-020-03020-3

Keywords

Critical Care

ISSN: 1364-8535